Niagen Bioscience Inc. said it has sold its ChromaDex Reference Standards business to LGC in an all-cash transaction, effective Feb. 24, 2026. The company said the divestiture is intended to streamline operations and sharpen its focus on NAD+ science, intellectual property, and commercial growth in the longevity market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602260702BIZWIRE_USPR_____20260226_BW997493) on February 26, 2026, and is solely responsible for the information contained therein.
Comments